drug · antibody
duvakitug
Phase 3updated 3mo agoby $TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Phase 3 (across all indications), with 4 investigational indications.
indications
indications
IBD (Crohn's + UC)
all catalysts(0)
nothing on the calendar yet
Trials studying duvakitug
- phase3A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- phase3An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- phase3An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- phase3A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
News(2)
- Merck’s $11B anti-TL1A bet delivers 1 win, 1 loss in midphase inflammatory disease trialsA phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback wa…fiercebiotech · 11d ago
- Teva nabs experimental Tourette drug in $700M Emalex buyoutA Jefferies analyst argued the deal — Teva’s largest in a decade — “makes sense” given the synergies between Emalex and the pharmaceutical giant’s neurology business.biopharma_dive · 3mo ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that